ecrin-mdr-crcClinical2018IPD Sharing (as of June 2019): NoColorectal cancer metastaticColorectal Neoplasms MalignantMetastatic, Previously-Treated, Microsatellite-Stable Colorectal CarcinomaColorectal carcinomaColorectal NeoplasmsNeoplasmsColorectal CarcinomaColorectal Neoplasms MalignantColorectal Cancer MetastaticColorectal NeoplasmsMetastatic, Previously-treated, Microsatellite-stable Colorectal CarcinomaNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2308907United Kingdom5NivolumabCXD101ECRIN MDRNot providedfalseA Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal CancerThis is a study to assess the safety and efficacy of CXD101 in combination with the PD-1 Inhibitor Nivolumab in patients with metastatic, previously-treated, Microsatellite-Stable (MSS) Colorectal Carcinoma (CRC). The primary hypothesis of this study is that CXD101 and anti-PD1 monoclonal antibody synergise the anti-tumour activity in MSS colorectal cancer patients (~95% of CRC) who do not seem to respond to anti-PD1 or -PD-L1 immunotherapy alone.2018-05-152308907NCT039936262017-004509-42